Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 19/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 17/20 | 0.66 |
| ▸ | CSNK2B | P67870 | 11/20 | 0.65 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932184 | 0.91 | CSNK2A1 (0.80) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687866 | 0.89 | CSNK2A1 (0.65) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687872 | 0.89 | CSNK2A1 (0.63) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4973941 | 0.85 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687867 | 0.85 | CSNK2A1 (0.62) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687925 | 0.85 | CSNK2A1 (0.60) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687931 | 0.85 | CSNK2A1 (0.63) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL11932645 | 0.84 | CSNK2A1 (0.64) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL13687919 | 0.84 | CSNK2A1 (0.56) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10169358 | 0.84 | CSNK2A1 (0.83) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012054493-A1 | DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.